Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

BMC Cancer

Table 2 Odds ratios with 95% confidence intervals for breast cancer and selective cyclooxygenase-2 (COX-2) inhibitors, and over the counter nonsteroidal anti-inflammatory drugs (OTC NSAIDS).

Compound	Number of Cases	Number of Controls	Age Adjusted OR (95% CI)	Multivariate OR^d(95% CI)
None/Infrequent Use ^a	262	453	1.00	1.00
COX-2 Inhibitors ^b	10	52	0.31 (0.16–0.64)	0.29 (0.14–0.59)
OTC NSAIDs ^c
Aspirin	15	40	0.51 (0.27–0.98)	0.49 (0.26–0.94)
Ibuprofen/Naproxen	11	52	0.37 (0.18–0.71)	0.37 (0.18–0.72)
Acetaminophen	8	16	0.92 (0.39–2.20)	1.02 (0.39–2.20)
Baby Aspirin	17	36	0.82 (0.40–1.40)	0.77 (0.42–1.41)

^aNo use of any NSAID or analgesic or infrequent use of no more than one pill per week for less than one year;
^bCOX-2 inhibitors include celecoxib, rofecoxib, valdecoxib, and meloxicam used daily for two years or more.
^cOver the counter (OTC) NSAIDs/analgesics used at least two times per week for two years or more.
^dMultivariate odds ratios are adjusted for continuous variables (age and body mass) and categorical variables (parity, menopausal status, family history, smoking, and alcohol intake).

ISSN: 1471-2407